NATURE MEDICINE, cilt.27, sa.9, ss.1646-1680, 2021 (SCI-Expanded)
Dysregulated immune features in a patient with a homozygous loss-of-function mutation in PDCD1 suggest that IL-6, IL-23, STAT3 and ROR gamma T might be potential targets for treatment of PD-1 blockade-induced autoimmunity.